Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

A Prospective Cohort Study on the Epidemiological Investigation, Diagnosis, and Treatment of Hepatic Encephalopathy

30 septembre 2026 mis à jour par: Chuanlong Zhu, The First Affiliated Hospital with Nanjing Medical University

Purpose Hepatic encephalopathy (HE) is a serious complication of liver cirrhosis that can cause memory loss, slow reaction, and even coma. In China, large-scale epidemiological data on HE are lacking, early diagnosis remains difficult, and treatment needs improvement. This study aims to investigate the prevalence of HE in Chinese liver disease patients and to explore better diagnostic methods and treatment strategies.

Design This is a prospective, multicenter cohort study led by Jiangsu Province Hospital, in collaboration with 7 other hospitals in Jiangsu Province. Between April 2026 and December 2029, the study plans to enroll over 700 patients with liver cirrhosis and 120 healthy volunteers.

What participants will do Participants will use a WeChat mini-program to perform simple cognitive tests (e.g., reaction speed, attention) regularly. They will be followed up at month 1, 3, 6 after enrollment, and then every six months. The research team will collect routine laboratory results, medication records, and quality-of-life data.

Benefits and risks Participants will receive closer health monitoring, which may help detect changes early. The study involves no additional drugs or invasive procedures, so risks are very low. All personal information will be kept strictly confidential and used only for medical research.

Voluntary participation Participation is completely voluntary, and participants can withdraw at any time without affecting their routine medical care.

Aperçu de l'étude

Description détaillée

Hepatic encephalopathy is a common and serious complication of liver cirrhosis, which greatly affects the quality of life and survival prognosis of patients and imposes a heavy burden on the medical and health system. Among patients with liver cirrhosis, the prevalence of overt hepatic encephalopathy is 10-14%, rising to 16-21% in decompensated liver cirrhosis patients, and reaching 10-50% in those who have undergone transjugular intrahepatic portosystemic shunt (TIPS). The prevalence of minimal hepatic encephalopathy (mHE) ranges from 20% to 80%. Currently, the diagnosis of hepatic encephalopathy still relies on exclusion, and the first-line treatments are lactulose and rifaximin. In summary, there are many patients with hepatic encephalopathy, diagnosis is difficult, and the treatment effect is also limited. Studying the specific conditions of Chinese patients, improving diagnostic methods, and exploring more precise treatment plans are of great significance for improving the quality of life of patients and reducing the medical burden.

Type d'étude

Observationnel

Inscription (Estimé)

700

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Jiangsu
      • Nanjing, Jiangsu, Chine
        • Jiangsu Province Hospital
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 75 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

People with liver cirrhosis are diagnosed by doctors through imaging, elastography, biopsy or clinical symptoms.

La description

Inclusion Criteria:

  • For patients with liver cirrhosis and the general healthy population, the diagnosis of liver cirrhosis is made by doctors based on imaging, elastography, biopsy or clinical symptoms.
  • The patients themselves and their accompanying family members have smart phones, are proficient in using WeChat and mini-programs, and have a stable network environment.
  • They voluntarily sign the informed consent form, have good compliance, and fully understand this study.

Exclusion Criteria:

  • Age < 18 years old;
  • Women planning to get pregnant, already pregnant or during lactation;
  • Incomplete relevant data information required;
  • Unable to proficiently use WeChat mini-program or unstable network environment;
  • Red-green color blindness or other irreparable visual impairments;
  • Heart, lung, or kidney failure or unstable vital signs;
  • Unwilling to participate in the study or unable to sign the informed consent form;
  • Any other situation that may interfere with the study assessment, increase the risk for the subjects, or affect their completion of the study, as judged by the researcher and deemed unsuitable for participating in this study;
  • Have participated in or are currently participating in other clinical trials within the past 3 months;

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: COHORT
  • Perspectives temporelles: PROSPECTIVE

Cohortes et interventions

Groupe / Cohorte
Intervention / Traitement
non-CHE

Patients who did not develop covert hepatic encephalopathy during the follow-up period

use a WeChat mini-program to perform simple cognitive tests (e.g., reaction speed, attention) regularly

CHE

Patients who develop covert hepatic encephalopathy during the follow-up period

use a WeChat mini-program to perform simple cognitive tests (e.g., reaction speed, attention) regularly

liver cirrhosis with sarcopenia

Patients who develop sarcopenia during the follow-up period

liver cirrhosis without sarcopenia

Patients who did not develop sarcopenia during the follow-up period

liver cirrhosis with decline in quality of life

During the follow-up period, there was a decline in quality of life.

liver cirrhosis without decline in quality of life

During the follow-up period, there was not a decline in quality of life.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
covert hepatic encephalopathy
Délai: from the time of enrollment until the end of the 2-year follow-up period

Patients classified as level 0-1 according to the West Haven classification. The West Haven classification system for hepatic encephalopathy, formally titled the West Haven Classification for Hepatic Encephalopathy, is a semi-quantitative grading system widely used in clinical practice and research to assess the severity of hepatic encephalopathy in patients with cirrhosis. The evaluation is based on a comprehensive clinical assessment of four domains: level of consciousness, intellectual and behavioural function (including orientation, personality, mood, and attention), neuromuscular function (including asterixis, tendon reflexes, and ataxia), and ability to perform activities of daily living. Using these criteria, hepatic encephalopathy is classified into grades ranging from a minimum of Grade 0 to a maximum of Grade 4.

from the time of enrollment until the end of the 2-year follow-up period

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Sarcopenia
Délai: From enrollment to the end of treatment at 2 years

Sarcopenia refers to the loss of muscle mass. The definition is based on the L3-SMI.

From enrollment to the end of treatment at 2 years
decline in quality of life
Délai: From enrollment to the end of treatment at 2 years

Evaluated through the SF-36(36-Item Short-Form Health Survey) scale. The SF-36 assesses nine health dimensions. For every dimension (after standard transformation), the minimum possible score is 0 and the maximum possible score is 100. A higher score always indicates a better health outcome or better quality of life.

From enrollment to the end of treatment at 2 years

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
liver transplantation
Délai: From enrollment to the end of treatment at 2 years
From enrollment to the end of treatment at 2 years
TIPS
Délai: From enrollment to the end of treatment at 2 years
From enrollment to the end of treatment at 2 years
DEATH
Délai: From enrollment to the end of treatment at 2 years

The patient died.

From enrollment to the end of treatment at 2 years

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 octobre 2026

Achèvement primaire (Estimé)

31 janvier 2028

Achèvement de l'étude (Estimé)

31 mars 2028

Dates d'inscription aux études

Première soumission

16 mai 2026

Première soumission répondant aux critères de contrôle qualité

24 mai 2026

Première publication (Réel)

29 mai 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

1 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

30 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner